(Total Views: 287)
Posted On: 01/27/2021 7:49:18 PM
Post# of 22465
I agree with you on this: It remains a great opportunity for the little guy who does his homework on QTMM.
At this point, looks like Innova and QMC HealthID are working well together.
Innova has sold $1.5B in tests and is scaling to 50X bigger, depending on where you put their start (at one point they were 1M tests production a day).
Face facts, a company wants to be able to sustain growth and to sustain a growing stock price, not just punch upward for a short time, like it has in the past. To do that, Squires built an ecosystem with QDX HealthID in the center of it that makes the rest of it work. Thats what will sustain higher stock price. We're still waiting on revenue.
Tell me what QMC's earned share of $1.5B in sales or of 50M tests/day will be and then we can talk. It ain't nothing.
At this point, looks like Innova and QMC HealthID are working well together.
Innova has sold $1.5B in tests and is scaling to 50X bigger, depending on where you put their start (at one point they were 1M tests production a day).
Face facts, a company wants to be able to sustain growth and to sustain a growing stock price, not just punch upward for a short time, like it has in the past. To do that, Squires built an ecosystem with QDX HealthID in the center of it that makes the rest of it work. Thats what will sustain higher stock price. We're still waiting on revenue.
Tell me what QMC's earned share of $1.5B in sales or of 50M tests/day will be and then we can talk. It ain't nothing.
(0)
(0)
